GlassScriptPhysician profile
Tiffany Leon
NPI 1558030080
$1,246.66
in general payments reported to CMS, 2019-2025
22 companies · $397 in 2025
The $397 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $69.83 · 2022: $335 · 2023: $340 · 2024: $105 · 2025: $397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $763 · Education: $78.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $763.30 |
| Education | $78.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $231.02 | 2024-2025 | Slynd |
| Novo Nordisk INC | $145.10 | 2022-2023 | Ozempic |
| Astellas Pharma US INC | $125.56 | 2025 | Veozah |
| Abbvie INC. | $85.59 | 2022-2025 | |
| Amgen INC. | $84.74 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $77.32 | 2022-2023 | Farxiga |
| Lilly USA, LLC | $66.99 | 2022-2023 | Mounjaro |
| Edwards Lifesciences Corporation | $56.91 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Mylan Specialty L.P. | $47.79 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.63 | 2023 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.46 | 2022 | |
| Shield Therapeutics INC | $34.09 | 2025 | |
| Pfizer INC. | $30.18 | 2023 | |
| Idorsia Pharmaceuticals US INC | $30.04 | 2023 | Quviviq |
| Merck Sharp & Dohme LLC | $29.80 | 2022-2023 | Verquvo, Belsomra |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $22.85 | 2025 | |
| Karyopharm Therapeutics INC. | $21.32 | 2021 | |
| Sanofi Pasteur INC. | $15.61 | 2023 | |
| Janssen Biotech, INC. | $15.42 | 2021 | |
| Coopersurgical, INC. | $15.26 | 2025 | Paragard T 380a |
| Janssen Pharmaceuticals, INC | $14.77 | 2022 | |
| Dexcom, INC. | $13.21 | 2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffany Leon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.